BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
BioNexus Gene Lab's price to sales ratio was 0.7× on Nov 11, 2026, against 0.9× a year earlier. Over the last 4 years it ranged from 0.4× to 448.3×, with a median of 7.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.7× | −0.1 |
| 2025 | Dec 31, 2025 | 0.7× | −4.7 |
| 2024 | Dec 31, 2024 | 5.4× | −3.7 |
| 2023 | Dec 29, 2023 | 9.1× | −135.9 |
| 2020 | Aug 31, 2020 | 145.0× | – |
See a number that looks wrong?